Simon Sturge

Mr Sturge has over 30 years of international leadership experience in both the biotechnology and pharmaceutical industries. He joins Kymab on 1 May 2019 from Merck KGaA, where he was Executive Vice President Global Strategy, Business Development & Global Operations.

Previously, he was Chief Operating Officer of Merck Healthcare, responsible for company’s global commercial and manufacturing operations. Over the past five years, he has been responsible for the continued growth in global sales at Merck KGaA, as well as the commercial launches of BAVENCIO®(anti-PD-L1 avelumab) in solid tumours and MAVENCLAD® (cladribine) for relapsing multiple sclerosis.

Prior to joining Merck KGaA, Mr Sturge served as Corporate Senior Vice President, Biopharmaceuticals at Boehringer Ingelheim, where he had responsibility for the research, development and commercialisation of the company’s global biosimilar portfolio. Before that, he held CEO roles at a number of healthcare companies including Celltech Biologics, and he served as founder and CEO of Ribotargets, which was acquired by British Biotech and subsequently renamed Vernalis.